Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rebif Gains New Multiple Sclerosis Rx Share Following Tysabri Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

Rebif is the leader in new prescription growth with a 22.4% share, an all-time high, at the end of March, Serono says. The company is focusing marketing of Rebif on efficacy, a message to which Tysabri helped draw attention. Serono expects Rebif to emerge as the global MS leader by 2006.
Advertisement

Related Content

Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says
Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says
Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance
Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Topics

Advertisement
UsernamePublicRestriction

Register

PS062062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel